A photo of Patrick McGann.

Member, Division of Hematology

Associate Professor, UC Department of Pediatrics

513-517-2234

513-636-6929

Board Certified

My Biography & Research

Biography

Dr. McGann is an academic pediatric hematologist with research focusing on improving outcomes for children with sickle cell anemia, both in the United States and across the world. His work globally has included time living in Angola to lead the Angola Sickle Cell Initiative, which implemented the country’s first newborn screening program for sickle cell anemia. His current research efforts include both laboratory-based efforts here in the United States focused on the pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea, as well as clinical research efforts to improve the diagnosis and outcomes for children with sickle cell anemia living in sub-Saharan Africa.

He is also actively involved in global hematology and global child health through such organizations as the Global Sickle Cell Disease Network, the Central African Sickle Cell Network (REDAC), the American Society of Hematology, and the AAP's Section on International Child Health (SOICH).

Additional Languages

Portuguese

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders

Research Divisions

Hematology, Cancer and Blood Diseases, Global Health



Blog Posts

Cincinnati Children’s Launches 6 COVID-19 Research Projects

Infectious Diseases and Vaccines

Cincinnati Children’s Launches 6 COVID-19 Research Projects

Patrick T. McGann, MD, MS, Ming Tan, PhD ...5/26/2020

Our 2019 Research Annual Report

Genomics and Development

Our 2019 Research Annual Report

Patrick T. McGann, MD, MS, John Hogenesch, PhD ...2/4/2020

My Education

MD: Tufts University School of Medicine, Boston, MA, 2006.

Residency: Pediatrics, Massachusetts General Hospital, Boston, MA, 2009.

Fellowship: Pediatric Hematology-Oncology, St. Jude Children's Research Hospital, 2009-2011; Baylor College of Medicine, 2011-2012.

MS: Clinical Research, Baylor College of Medicine, 2013.

Board Certification: Pediatrics, 2009; Pediatric Hematology-Oncology, 2013.

My Publications

Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease. Karkoska, K; Quinn, CT; Clapp, K; McGann, PT. American Journal of Hematology. 2020; 95:E338-E339.

AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings. Perez-Plazola, MS; Tyburski, EA; Smart, LR; Howard, TA; Pfeiffer, A; Ware, RE; Lam, WA; McGann, PT. BMC Medicine. 2020; 18.

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Meier, ER; Creary, SE; Heeney, MM; Dong, M; Appiah-Kubi, AO; Nelson, SC; Niss, O; Piccone, C; Quarmyne, MO; Quinn, CT; et al. Trials. 2020; 21.

When actions speak louder than words — Racism and sickle cell disease. Power-Hays, A; McGann, PT. The New England journal of medicine. 2020; 383:1902-1903.

Non-transfusion-dependent ß-thalassemia because of a single ß-thalassemia mutation and coinherited a-globin gene triplication: Need for increased awareness to prevent incorrect and delayed diagnosis. Gurunathan, A; Tarango, C; McGann, PT; Niss, O; Quinn, CT. Journal of Pediatric Hematology/Oncology. 2020; 42:e494-e496.

Non–transfusion-dependent β-Thalassemia Because of a Single β-Thalassemia Mutation and Coinherited α-Globin Gene Triplication: Need for Increased Awareness to Prevent Incorrect and Delayed Diagnosis. Gurunathan, A; Tarango, C; McGann, PT; Niss, O; Quinn, CT. Journal of Pediatric Hematology/Oncology. 2020; 42:e494-e496.

The increasing global burden of childhood disability: A call for action. Vawter-Lee, M; McGann, PT. Pediatrics. 2020; 146:e20201119-e20201119.

End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings. Farrell, AT; Panepinto, J; Desai, AA; Kassim, AA; Lebensburger, J; Walters, MC; Bauer, DE; Blaylark, RM; DiMichele, DM; Gladwin, MT; et al. Blood Advances. 2019; 3:4002-4020.

Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. Ware, RE; McGann, PT; Quinn, CT. Pediatric Blood and Cancer. 2019; 66.

Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. American Journal of Hematology. 2019; 94:871-879.